N
Noelle V. Frey
Researcher at University of Pennsylvania
Publications - 197
Citations - 10555
Noelle V. Frey is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Transplantation & Medicine. The author has an hindex of 38, co-authored 161 publications receiving 7286 citations. Previous affiliations of Noelle V. Frey include Hospital of the University of Pennsylvania & Medical College of Wisconsin.
Papers
More filters
Journal ArticleDOI
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
Daniel W. Lee,Bianca Santomasso,Frederick L. Locke,Armin Ghobadi,Cameron J. Turtle,Jennifer N. Brudno,Marcela V. Maus,Jae H. Park,Elena Mead,Steven Z. Pavletic,William Y. Go,Lamis K. Eldjerou,Rebecca Gardner,Noelle V. Frey,Kevin J. Curran,Karl S. Peggs,Marcelo C. Pasquini,John F. DiPersio,Marcel R.M. van den Brink,Krishna V. Komanduri,Stephan A. Grupp,Sattva S. Neelapu +21 more
TL;DR: The goal is to provide a uniform consensus grading system for CRS and neurotoxicity associated with immune effector cell therapies, for use across clinical trials and in the postapproval clinical setting.
Journal ArticleDOI
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
David L. Porter,Wei-Ting Hwang,Noelle V. Frey,Simon F. Lacey,Pamela A. Shaw,Alison W. Loren,Adam Bagg,Katherine T. Marcucci,Angela Shen,Vanessa E. Gonzalez,David E Ambrose,Stephan A. Grupp,Anne Chew,Zhaohui Zheng,Michael C. Milone,Bruce L. Levine,J. Joseph Melenhorst,Carl H. June +17 more
TL;DR: The in vivo expansion of theCAR T cells correlated with clinical responses, and the CAR T cells persisted and remained functional beyond 4 years in the first two patients achieving CR, suggesting that disease eradication may be possible in some patients with advanced CLL.
Journal ArticleDOI
Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
Joseph A. Fraietta,Simon F. Lacey,Elena Orlando,Iulian Pruteanu-Malinici,Mercy Gohil,Stefan Lundh,Alina C. Boesteanu,Yan Wang,Roddy S. O’Connor,Wei-Ting Hwang,Edward Pequignot,David E Ambrose,Changfeng Zhang,Nicholas Wilcox,Felipe Bedoya,Corin L. Dorfmeier,Fang Chen,Lifeng Tian,Harit Parakandi,Minnal Gupta,Regina M. Young,F. Brad Johnson,Irina Kulikovskaya,Li Liu,Jun Xu,Sadik H. Kassim,Megan M. Davis,Bruce L. Levine,Noelle V. Frey,Don L. Siegel,Alexander C. Huang,E. John Wherry,Hans Bitter,Jennifer Brogdon,David L. Porter,Carl H. June,J. Joseph Melenhorst +36 more
TL;DR: A mechanistically relevant population of CD27+PD-1–CD8+ CAR T cells expressing high levels of the IL-6 receptor predicts therapeutic response and is responsible for tumor control, and new features of CAR T cell biology are uncovered.
Journal ArticleDOI
Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T cell Therapy for Acute Lymphoblastic Leukemia
David T. Teachey,David T. Teachey,Simon F. Lacey,Pamela A. Shaw,J. Joseph Melenhorst,Shannon L. Maude,Noelle V. Frey,Edward Pequignot,Vanessa E. Gonzalez,Fang Chen,Jeffrey Finklestein,David M. Barrett,Scott L. Weiss,Julie C. Fitzgerald,Robert A. Berg,Richard Aplenc,Colleen Callahan,Susan R. Rheingold,Zhaohui Zheng,Stefan Rose-John,Jason C. White,Farzana Nazimuddin,Gerald Wertheim,Bruce L. Levine,Carl H. June,David L. Porter,Stephan A. Grupp +26 more
TL;DR: The first models that can accurately predict which patients are likely to develop severe CRS before they become critically ill are developed, which improves understanding of CRS biology and may guide future cytokine-directed therapy.
ASBMT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
DW Lee,Bianca Santomasso,Frederick L. Locke,Armin Ghobadi,Cameron J. Turtle,Jennifer N. Brudno,Marcela V. Maus,JH Park,Elena Mead,Steven Z. Pavletic,WY Go,Lamis K. Eldjerou,Rebecca Gardner,Noelle V. Frey,Kevin J. Curran,Karl S. Peggs,Marcelo C. Pasquini,John F. DiPersio,Mrm van den Brink,Krishna V. Komanduri,Stephan A. Grupp,Sattva S. Neelapu +21 more
TL;DR: In 2018, the American Society for Blood and Marrow Transplantation (ASBMT) recognized the need to harmonize the definitions and grading systems for cytokine release syndrome (CRS) and neurotoxicity associated with CAR T cell therapies.